<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04697355</url>
  </required_header>
  <id_info>
    <org_study_id>IRB FWA 00006218</org_study_id>
    <nct_id>NCT04697355</nct_id>
  </id_info>
  <brief_title>Effect of Naringenin and Beta Carotene on Energy Expenditure</brief_title>
  <official_title>Case Study to Evaluate the Safety and Effect on Energy Expenditure of Naringenin and Beta Carotene</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pennington Biomedical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pennington Biomedical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to test the effects of the combination of naringenin (from an extract&#xD;
      of sweet oranges) and beta carotene on energy expenditure and glucose metabolism in a single&#xD;
      human subject.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subject will be treated for 8 weeks with the combination of naringenin + beta carotene.&#xD;
&#xD;
      We will conduct the following assessments before the treatment and at the end of eight weeks.&#xD;
&#xD;
        1. Resting metabolic rate&#xD;
&#xD;
        2. Oral glucose tolerance test with glucose and insulin&#xD;
&#xD;
        3. Ambulatory blood pressure&#xD;
&#xD;
        4. Recording of adverse events&#xD;
&#xD;
        5. Body weight&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 19, 2021</start_date>
  <completion_date type="Actual">August 2, 2021</completion_date>
  <primary_completion_date type="Actual">June 16, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Case study in a single human subject</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Energy expenditure</measure>
    <time_frame>Five hours</time_frame>
    <description>Ventilated hood</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events</measure>
    <time_frame>Eight weeks</time_frame>
    <description>Adverse events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose metabolism</measure>
    <time_frame>Three hours</time_frame>
    <description>Oral glucose tolerance test with insulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>24 hours</time_frame>
    <description>Ambulatory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>16 weeks</time_frame>
    <description>Measurement of body weight</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Energy Expenditure</condition>
  <condition>Safety Issues</condition>
  <condition>Glucose Metabolism</condition>
  <arm_group>
    <arm_group_label>Naringenin + Beta carotene</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>naringenin and beta carotene</intervention_name>
    <description>Subject will ingest 300 mg naringenin three times/day and 6 mg beta carotene two times/day for eight weeks</description>
    <arm_group_label>Naringenin + Beta carotene</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Fasting blood glucose &lt; 200mg/dL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to citrus fruits&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank L Greenway, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Murugesan N, Woodard K, Ramaraju R, Greenway FL, Coulter AA, Rebello CJ. Naringenin Increases Insulin Sensitivity and Metabolic Rate: A Case Study. J Med Food. 2020 Mar;23(3):343-348. doi: 10.1089/jmf.2019.0216. Epub 2019 Oct 31.</citation>
    <PMID>31670603</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 4, 2021</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 6, 2021</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pennington Biomedical Research Center</investigator_affiliation>
    <investigator_full_name>Frank Greenway</investigator_full_name>
    <investigator_title>Chief Medical Officer</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Beta Carotene</mesh_term>
    <mesh_term>Naringenin</mesh_term>
    <mesh_term>Carotenoids</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

